Integrated Pharmacy Research and Practice

Integrated Pharmacy Research and Practice is an international, peer-reviewed, open access journal published by Dove Medical Press, the Auckland imprint that has formed part of the Taylor & Francis Group since 2023.《整合药学研究与实践》是一份国际同行评审开放获取期刊，由位于奥克兰的 Dove Medical Press 出版，该品牌自 2023 年起并入 Taylor & Francis 集团。

Launched in 2012, it carries a 2025 Journal Impact Factor of 2.4 and sits in the third quartile of the pharmacology and pharmacy listing of the Emerging Sources Citation Index, with about twenty papers appearing each year.该刊创办于 2012 年，2025 年期刊影响因子为 2.4，在新兴来源引文索引的药学与药理学类目位列第三四分位，每年刊出的论文约二十篇。

Scope

• The remit is drawn around academic and professional pharmacy practice, following a medicine from formulation and regulation through dispensing to the bedside and to the patient's own home.收稿范围围绕学术药学和职业药学实践划定，关注药品从制剂、监管、调剂一路走到病床边与患者家中的全过程。
• Clinical pharmacy work in hospitals is central, including ward-based review of prescriptions, therapeutic drug monitoring, and the design of services that pharmacists deliver alongside medical teams.医院临床药学工作是核心板块，涵盖病区处方审核与治疗药物监测，也涵盖药师同医疗团队协同开展的服务设计。
• Community pharmacy and primary care form a second cluster, with papers on counselling at the counter, minor ailment schemes, and the shifting boundary between self-care and referral.社区药房与基层医疗构成第二个板块，相关论文讨论柜台用药咨询、轻微病症处理方案，也讨论自我照护与转诊之间不断移动的边界。
• Adherence and persistence attract steady attention, from measurement methods and the reasons patients abandon long-term therapy to interventions that general practices and pharmacy chains can actually sustain.用药依从性与持续性受到持续关注，从测量方法、患者放弃长期治疗的原因，到基层诊所与连锁药房真正能维持下去的干预措施。
• Medication review and deprescribing in older people, above all where polypharmacy meets frailty, are treated as clinical problems rather than as bookkeeping exercises.老年患者的用药审核与减药处方被当作临床问题处理，多药共用与衰弱状态叠加的情形尤其受到重视，并未被降格为台账工作。
• Pharmacovigilance runs through the journal, covering spontaneous reporting, signal detection from routine data, and the communication of newly identified risks to prescribers and to the public.药物警戒贯穿刊物各栏目，涉及自发报告、常规数据中的信号探测，也涉及把新识别的风险传达给处方医生与公众。
• Pharmacoepidemiology and real-world evidence appear frequently, with cohort and case-control designs built on claims databases, disease registries and national prescribing records.药物流行病学与真实世界证据出现频繁，相关研究基于理赔数据库、疾病登记系统与国家处方记录构建队列与病例对照设计。
• Education and workforce questions are in scope as well, from undergraduate curriculum and simulation-based training to continuing professional development and the task shifting that many health systems now attempt.教育与人力议题同样在列，从本科课程、模拟训练，到继续职业发展，再到许多卫生体系正在尝试的任务转移。
• Health services research and pharmacoeconomics bring cost-effectiveness analysis, budget impact modelling and equity considerations into a journal whose readers mostly work inside dispensing budgets.卫生服务研究与药物经济学把成本效果分析、预算影响建模与公平性考量带进这份刊物，其读者大多在调剂预算之内工作。
• Policy and regulation receive room, including prescribing rights, scope-of-practice reform, pricing and reimbursement rules, and the inspection regimes that govern compounding and distribution.政策与监管占有一定篇幅，包括处方权、执业范围改革与定价报销规则，也包括管理调配和流通的检查制度。
• Digital practice is covered through e-prescribing, telepharmacy, automated dispensing and clinical decision support, with attention to what happens when the software is wrong or the network fails.数字实践通过电子处方、远程药学、自动调剂与临床决策支持进入视野，并关注软件出错或网络中断时的实际后果。
• Antimicrobial stewardship sits at the intersection of pharmacy and infection control, and papers here examine audit and feedback, prescribing restrictions and the role of the pharmacist on stewardship rounds.抗菌药物管理处在药学与感染控制的交叉处，此类论文考察审计反馈与处方限制，也考察药师在管理查房中的角色。
• Interprofessional collaboration and transitions of care are recurring subjects, since medication errors cluster where responsibility passes between hospital, community pharmacy and nursing home.跨专业协作与照护转接是反复出现的主题，用药错误往往集中在医院、社区药房与养老机构之间移交责任的环节。
• Work from low- and middle-income settings is welcomed, particularly on access, affordability and the informal sale of medicines, subjects that dominate practice outside high-income markets.来自中低收入环境的研究受到欢迎，尤其是可及性、药品可负担性与非正规销售，这些议题在发达市场之外的实践中占主导。
• Original research, reviews, case series and commentary are all accepted, and the journal states that submissions should carry implications reaching beyond a single institution.原创研究、综述、病例系列与评论均在接纳之列，刊物明确要求来稿给出超越单一机构的意涵。

History

• Dove Medical Press opened the title in 2012, issuing volume 1 from its Auckland office as part of a portfolio built entirely on open access.Dove Medical Press 于 2012 年创办该刊，在奥克兰办事处推出第 1 卷，这份刊物属于一个完全建立在开放获取之上的刊群。
• The National Library of Medicine catalogs it as 「Integrated pharmacy research and practice」 under the abbreviation 「Integr Pharm Res Pract」, and PubMed coverage begins with volume 4 in 2015.美国国家医学图书馆将其著录为「Integrated pharmacy research and practice」，缩写取「Integr Pharm Res Pract」，PubMed 收录自 2015 年第 4 卷开始。
• Articles are deposited in PubMed Central as well, so the full text of most papers is freely available without a subscription.论文同时存入 PubMed Central，因此多数文章全文无需订阅即可获取。
• One volume a year has been the pattern throughout. Volume 1 covers 2012, volume 14 covers 2025, and volume 15 opened in 2026, with no issue numbers dividing the annual volume.一年一卷是始终未变的格局。第 1 卷对应 2012 年，第 14 卷对应 2025 年，第 15 卷已于 2026 年开启，年度卷内不再划分期号。
• Publication is continuous, so an accepted paper is typeset and posted once the proofs are cleared, and the volume fills up in the order that articles are ready.出版采取连续方式，录用的论文在校样确认后即排版上线，整卷按文章就绪的先后顺序填充。
• Gold open access was the model from the first issue, with costs met by an article processing charge and no subscription edition ever offered.金色开放获取自创刊号起即为既定模式，费用由文章处理费承担，从未发行过订阅版。
• Clarivate placed the title in the Emerging Sources Citation Index, and a Journal Impact Factor has come with the release since 2023, when the figure stood at 2.1.Clarivate 将该刊收入新兴来源引文索引，自 2023 年发布起给出期刊影响因子，当年数值为 2.1。
• The metric held at 2.1 in 2024 and rose to 2.4 in 2025, while the five-year figure now stands at 2.5.该指标 2024 年保持在 2.1，2025 年升至 2.4，五年期数值现为 2.5。
• In the 2025 Journal Citation Reports the journal ranks 215 of 356 in pharmacology and pharmacy, with a Journal Citation Indicator of 0.55 and a percentile of 39.7.在 2025 年期刊引证报告中，该刊在药学与药理学类目位列 215/356，期刊引证指标为 0.55，百分位为 39.7。
• Total citations recorded in the same report reached 580, and a cited half-life of 6.6 years is long for a title of this size.同一份报告记录的总被引次数为 580，6.6 年的引用半衰期对这样规模的刊物而言偏长。
• Taylor & Francis Group acquired Dove Medical Press in 2023, and the publisher's pages now carry the line that Dove Medical Press is part of Taylor & Francis Group.Taylor & Francis 集团于 2023 年收购 Dove Medical Press，出版方页面现在标注「Dove Medical Press is part of Taylor & Francis Group」。
• Despite the change of owner, the journal continues to appear under the Dove imprint, and its title, its scope and its volume numbering were left untouched.尽管所有者变更，刊物仍以 Dove 品牌出版，刊名、收稿范围与卷号体系均未改动。
• Output has remained modest, with 20 papers indexed for 2022, 19 for 2023 and 22 for 2024 in the Crossref record.发文量始终不大，按 Crossref 记录，2022 年收录 20 篇，2023 年为 19 篇，2024 年为 22 篇。
• The title has never been renamed, so the volume sequence that began in 2012 runs unbroken into the current year, and no former title has to be tracked in citations.该刊从未更名，2012 年起始的卷号一路延续到今年，引用时无需追溯任何旧题名。
• Listing in the Directory of Open Access Journals dates from the launch year as well, and the entry has stayed in place ever since.开放获取期刊目录的收录同样可追溯到创刊当年，此后一直保留在列。

Editors

• Walid Al-Qerem, professor at the Faculty of Pharmacy of Al-Zaytoonah University of Jordan, holds the editor-in-chief position.主编由约旦扎耶通纳大学药学院教授（Walid Al-Qerem）担任。
• He took his PhD in clinical pharmacy at the University of Sunderland, and his research builds spirometric reference equations for asthma and COPD, population-specific growth charts, and instruments that measure health-related quality of life and adherence to medication.他在英国桑德兰大学取得临床药学博士学位，研究包括为哮喘与慢性阻塞性肺疾病建立肺量计参考方程，编制适合特定人群的生长曲线，以及开发用于评估健康相关生存质量与用药依从性的量表。
• Fawaz Alasmari of the Department of Pharmacology and Toxicology at King Saud University in Riyadh serves as associate editor in chief, and his own work concerns the toxicology of drugs of abuse.副主编为沙特国王大学（King Saud University）药理学与毒理学系的（Fawaz Alasmari），其研究关注滥用药物毒理学。
• The editorial board lists 17 members from 13 countries, four of them in the United States and two in India, with the rest spread from Portugal and Spain to Iran, Malaysia, Singapore and New Zealand.编委会列出 13 个国家的 17 位成员，其中美国 4 位、印度 2 位，其余分布在葡萄牙与西班牙，也分布在伊朗、马来西亚、新加坡与新西兰。
• Adam Todd of the School of Pharmacy at Newcastle University in the United Kingdom carries the title of founding editor-in-chief on the same page.同一页面还列出（Adam Todd，英国纽卡斯尔大学药学院），署衔为创刊主编。
• Manuscripts undergo desk assessment first. Those that fall outside the remit, or that lack the data to support their claims, are returned without external review.稿件首先经过编辑初审。超出收稿范围、或数据不足以支撑结论的来稿，不经外审即退回。
• Papers that pass are sent to independent referees, and a revision is expected to answer each point raised, with the editor adjudicating where the reports disagree.通过初审的论文送交独立审稿人，修回稿须逐条回应所提问题，意见分歧时由主编裁定。
• Submission runs through the publisher's online system, and no pre-submission enquiry is required before a full manuscript is uploaded.投稿经出版方的在线系统完成，上传完整稿件之前无需预先询问编辑部。
• The journal publishes original research, reviews, case series and commentary, and it asks authors to show how findings would change practice rather than merely report them.刊物发表原创研究、综述、病例系列与评论，并要求作者说明研究结果将如何改变实践，仅仅报告结果并不足够。
• Declarations of funding and of competing interest are mandatory, and submissions are screened for overlap with earlier work before referees see them.资助来源与利益冲突声明为强制项，稿件在送审之前会做与已发表工作的重复度筛查。
• Editorial conduct follows the guidelines of the Committee on Publication Ethics, which the imprint applies across its list.编辑行为遵循出版伦理委员会的准则，该品牌在其全部刊物中统一执行。
• Authors keep copyright, and the licence allows reuse with attribution, a condition that matters to readers who teach from the papers.作者保留版权，许可允许在署名前提下复用，这对以论文授课的读者尤为实用。